UK researchers receive grant to study link between manmade chemicals and heart disease

The British Heart Foundation is to fund research exploring the link between Bisphenol A (BPA), a manmade chemical found in commonly used plastics, and heart disease. The grant is for -119,169.

In the UK, 2∙6 million people are living with heart disease. Studies have suggested that some manmade chemicals might be linked to development of heart disease, including bisphenol A (BPA) that is used in some types of plastic containers.

A research team from Peninsula College of Medicine and Dentistry in Exeter and the University of Exeter will try to confirm whether BPA may cause heart disease. They will measure levels of BPA in about 1,000 people who are receiving bypass surgery for heart disease at Papworth Hospital in Cambridgeshire to see if there is a link.

They will also look at BPA levels among a study group of thousands of people from Norfolk, who have been followed for more than 10 years as part of an ongoing research project to look at the development of heart disease. Clarifying whether BPA is linked to heart disease could impact public health by leading to potential controls on its use.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers uncover immune mechanism behind myocarditis from cancer immunotherapy